Focused On-demand Library for Mitochondrial chaperone BCS1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9Y276

UPID:

BCS1_HUMAN

Alternative names:

BCS1-like protein

Alternative UPACC:

Q9Y276; B3KTW9; Q7Z2V7

Background:

Mitochondrial chaperone BCS1, also known as BCS1-like protein, is pivotal for the assembly of mitochondrial respiratory chain complex III. It plays a crucial role in maintaining mitochondrial tubular networks, respiratory chain assembly, and the formation of the LETM1 complex. This protein's functionality underscores its importance in cellular energy production and distribution.

Therapeutic significance:

The protein is linked to diseases such as GRACILE syndrome, Mitochondrial complex III deficiency, nuclear type 1, and Bjoernstad syndrome. These conditions highlight the protein's critical role in mitochondrial function and energy metabolism. Understanding the role of Mitochondrial chaperone BCS1 could open doors to potential therapeutic strategies for these mitochondrial disorders.